By inhibiting type 2 cytokine signaling, dupilumab markedly improves dermatitis manifestations and restores epidermal barrier function through increased expression of filaggrin and tight-junction proteins, leading to reduced transepidermal water loss and enhanced activity of antimicrobial peptides (3). Here, FLG is linked to dermatitis.